Sage Therapeutics Культура компании

Dr. Stephen J. Kanes, M.D., Ph.D. has been the Chief Medical Officer of Sage Therapeutics, Inc. since August 14, 2013. Dr. Kanes was practicing psychiatrist and served as the Executive Director/Therapeutic Area Clinical Director for the Inflammation, Neuroscience and Respiratory GMED division of AstraZeneca Pharmaceuticals. During his time at AstraZeneca, he also served as Medical Science Senior Director for the neuroscience established brands and emerging anesthesia Global Product Team and in other positions of increasing responsibility in the Neuroscience Discovery Medicine, early and late development groups. He serves as an adjunct assistant professor of psychiatry at the University of Pennsylvania School of Medicine. Prior to joining AstraZeneca, Dr. Kanes was a faculty member in the Psychiatry Department at the University of Pennsylvania School of Medicine. Dr. Kanes received his B.A. from the University of Pennsylvania and both his Ph.D. and M.D. from State University of New York???Stony Brook. Dr. Kanes completed his psychiatry residency at Yale-New Haven Medical Center and postdoctoral fellowship at the University of Pennsylvania.

Dr. Albert J. Robichaud, also known as Al, Ph.D. has been the Chief Scientific Officer of Sage Therapeutics, Inc. since November 2011. Dr. Robichaud was responsible for advancing Sage Therapeutics therapeutic pipeline for CNS disorders and moving its lead programs into clinical development. Dr. Robichaud has an extensive portfolio of drug discovery experience focused in the neuroscience arena. He served as vice president of chemistry and pharmacokinetic sciences at Lundbeck Research USA, he was responsible for the drug discovery, analytical, computational and pharmacokinetics departments focused on synaptic transmission and neuroinflammation. Dr. Robichaud was Senior Director and Head of the Neuroscience Discovery Chemistry department of Wyeth Research. During his tenure there, his group successfully delivered more than 15 drug candidates for clinical development in a broad range of neuroscience indications. Dr. Robichaud serves as a Member of Scientific Advisory Board of Morphic Rock Therapeutic, Inc. He has more than 20 years of drug discovery experience focused primarily in the neuroscience arena. Dr. Robichaud has co-authored more than 125 manuscripts and abstracts and is a co-inventor on 45 patents and patent applications. Dr. Robichaud earned a B.S. in chemistry from Rensselaer Polytechnic Institute, a Ph.D. in organic chemistry from the University of California, Irvine and was an American Chemical Society postdoctoral fellow at Colorado State University.

Ms. Kimi E. Iguchi, CPA, has been the Chief Financial Officer of Sage Therapeutics, Inc. since August 14, 2013 and serves as its Treasurer. Ms. Iguchi served as Principal Accounting Officer of Cyberkinetics Neurotechnology Systems Inc. until May 31,2007. Ms. Iguchi also served as Principal Financial Officer of Cyberkinetics Neurotechnology Systems Inc. and its Vice President of Finance from August 2004 to May 31,2007. Prior to joining Cyberkinetics in 2004, she served as Senior Director of Finance of Millennium Pharmaceuticals Inc., was responsible for corporate finance, long range planning, developing and implementing key financial systems and processes. She also served as Financial Manager of Millennium BioTherapeutics, Inc., a former subsidiary of Millennium Pharmaceuticals, Inc. She served as the Chief Operating Officer, North America, for Santhera Pharmaceuticals. Ms. Iguchi served as Head of the Biotherapeutics subsidiary and as its Senior Director of Financial Planning and Analysis. She served as the Senior Manager of External Reporting of Biogen, Inc. from October 1996 to May 1998. Prior to that, from September 1995 to October 1996, she served as Director of Financial Reporting of Continental Cablevision. From May 1998 to March 2004, she worked in a variety of roles at Millennium Pharmaceuticals. From 1996 to 1997, Ms. Iguchi served as Senior Manager of External Reporting at Biogen IDEC. Previously, Ms. Iguchi served as a Senior Audit Manager of Pricewaterhouse Coopers LLP. Ms. Iguchi is a CPA and was a public accountant at Coopers and Lybrand from 1987 to 1995. Ms. Iguchi received her B.S. in Chemistry from Drew University in 1984 and an M.B.A. from Northeastern University in 1987.

Ms. Anne Marie Cook, Esq. has been Senior Vice President and General Counsel of Sage Therapeutics, Inc., since September 21, 2015 and has been its Corporate Secretary since December 2015. Ms. Cook served as Senior Vice President, Secretary and General Counsel of Aegerion Pharmaceuticals, Inc. from December 2011 to September 2015. She was a Partner with Boston-based law firm, Choate Hall & Stewart LLP. She served as a General Counsel of ViaCell Inc. since September 6, 2005 and serves as its Corporate Secretary and Senior Vice President of Business Development. Ms. Cook led the Cambridge office of Miller, Canfield, Paddock and Stone, P.L.C. Ms. Cook was responsible for managing its corporate legal affairs and business development activities at ViaCell. She served as Senior Vice President of Legal of ViaCell Inc. since September 6, 2005. Ms. Cook joined ViaCell from Biogen Idec Inc. (now known as Biogen Inc.). Ms. Cook served as Secretary of Biogen Idec Inc. until January 2006. Ms. Cook served as Acting General Counsel of Biogen Idec Inc. from March 2005 to January 2006. From November 2003 to March 2005, Ms. Cook served as Vice President and Chief Corporate Counsel at Biogen Idec Inc. Prior to the merger, Ms. Cook served as Vice President, Chief Corporate Counsel of Biogen, Inc., a position she held from October 2001 to November 2003. Before that, she served as Associate General Counsel, Chief Corporate Counsel of Biogen, Inc. from June 1999 to October 2001, Associate General Counsel of Biogen, Inc. from December 1995 to June 1999 and Assistant General Counsel of Biogen, Inc. from November 1992 to December 1995. As Vice President, Chief Corporate Counsel at Biogen Idec, Ms. Cook oversaw its U.S. corporate legal matters pertaining to securities law, FDA compliance, product collaboration and license agreements, mergers and acquisitions and commercial contracts and litigation. Before joining Biogen, Inc., Ms. Cook was an associate in the corporate group of Testa, Hurwitz & Thibeault, LLP. She holds a B.S. in Biology from Tufts University and a J.D. from University of Notre Dame Law School.

Dr. Amy Schacterle, Ph.D., has been Senior Vice President of Regulatory Affairs and Quality Assurance at Sage Therapeutics, Inc. since April 24, 2017. Dr. Schacterle served as Vice President of Regulatory Affairs and Quality Assurance at Sage Therapeutics, Inc. since February 13, 2015 until April 24, 2017. Dr. Schacterle has 22 years of experience in the biotech and life science industries, including 15 years in executive management. She served as vice president, regulatory affairs at Sunovion Pharmaceuticals (previously Sepracor), where she worked for 10 years, also serving as executive director and senior director of regulatory affairs. At Sunovion, she led regulatory strategy regarding clinical development of CNS compounds and later managed development and commercial regulatory activities for all drug, biologic and combination device products at the company's Marlborough campus. Prior to Sunovion, Dr. Schacterle spent seven years leading the regulatory affairs function at Stryker Biotech, where she determined successful regulatory strategies for biologic orthopaedic products and was an integral part of the quality team. Dr. Schacterle was named as one of Boston Business JournalMass High Tech 2014 Women to Watch. Dr. Schacterle received her B.S. in biomedical engineering at Rensselaer Polytechnic Institute and her Ph.D. and M.S. in biomedical engineering at the University of Virginia.

Mr. Thomas D. Anderson, also known as Tom, has been the Chief Commercial Strategy Officer at Sage Therapeutics, Inc. since May 2014. Prior to joining SAGE, Mr. Anderson served as senior vice president, corporate strategy and commercial assessment at Shire plc and served as general manager for several of Shire's psychiatry and neurology products. In addition, he led Shire's specialty pharmaceutical's commercial operations, business information and strategic marketing functions and played a lead role in business development efforts. Prior to Shire and in two separate tenures, he spent 17 years in Johnson & Johnson's pharmaceutical companies, notably Janssen and Ortho-McNeil, where he held senior-level roles in marketing, marketing research, sales and sales management, operations and engineering. In between employments at Johnson & Johnson, he was president and chief executive officer of Ranir Corporation, a dental products company and executive vice president and chief operating officer of Lander Co., Inc., a healthcare-related consumer packaged goods company and was a corporate officer and director at both companies. Mr. Anderson received his B.S. in civil engineering from Lehigh University and his MBA in finance from the University of Notre Dame.

Mr. Michael Cloonan, also known as Mike, has been Chief Business Officer at Sage Therapeutics, Inc. since April 24, 2017. Mr. Cloonan leads Sage's Commercial, Portfolio and Program Management, Medical Affairs and Corporate Development departments. Mr. Cloonan worked for 14 years at Biogen and served as its Senior Vice President, US Commercial, where he led a US affiliate with direct general manager responsibility for Sales, Marketing, Market Access, Patient Services and Commercial Operations. Previously, he held roles of increasing responsibility at Biogen, including Senior Vice President, Global Commercial Strategy; Vice President, Managing Director, Australia/New Zealand affiliate; and Vice President, Business Planning. Prior to Biogen, Mr. Cloonan worked at Bain & Company as a consultant specializing in healthcare. Mr. Cloonan received his M.B.A. from Darden Graduate School of Business Administration, University of Virginia and a B.A. from College of the Holy Cross.

Dr. Christopher J. Silber, also known as Chris, M.D., has been Senior Vice President of Clinical Development at Sage Therapeutics, Inc. since April 24, 2017. Dr. Silber served as the Chief Medical Officer of Agilis Biotherapeutics, LLC since January 25, 2016. Dr. Silber served as Vice President of US Clinical Development Center at Lundbeck A/S. He served as a Vice President of Clinical Affairs of Lundbeck Inc. since March 4, 2008. Prior to joining Agilis, he spent seven years at H. Lundbeck A/S. He served as Executive Medical Director of Takeda and Global Development Team Leader for its diabetic neuropathy and neuropathic pain clinical programs. He has more than 25 years of clinical development leadership experience in the pharmaceutical industry including orphan drug development, with extensive therapeutic experience in neuroscience. He led drug development for Hospira's critical care and generics portfolios following 13 years at Abbott Laboratories in a variety of clinical research roles, including his roles as Venture Head in analgesia and psychopharmacology where he led overall drug development. Following training in family medicine at Duke University Medical Center, he served as Assistant Medical Director of Forest Laboratories, working in the area of Alzheimer's disease. He began his career in industry at Forest Laboratories as a medical monitor for clinical trials in Alzheimer's Disease. Mr. Silber received his M.D from the School of Medicine at the State University of New York at Buffalo and his Bachelor of Arts degree in Psychology from Tufts University.

Dr. Jim Doherty, Ph.D., has been the Senior Vice President of Research at Sage Therapeutics, Inc. since September 21, 2015. Dr. Doherty served as Vice President of Pharmacology and Head of Biology at Sage Therapeutics, Inc. He joined SAGE in 2012. Prior to, he served as Director and Head of the Neuroscience Department for the CNS and Pain Innovative Medicine Unit of AstraZeneca Pharmaceuticals in Sodertalje, Sweden. Prior to, he SERVEDA S Director and Head of the Neuroscience Department at AstraZeneca Pharmaceuticals in Wilmington, Del. He has experience with discovery, translational science and early development in several areas of neuroscience research, including psychiatry, neurology, cognition, epilepsy and analgesia. He has authored more than 30 peer-reviewed research and review articles. He was a postdoctoral fellow at Emory University Medical School. Dr. Doherty holds a B.A. in biology from the University of Delaware and a Ph.D. in neuroscience from Georgetown University.